Loading...
Market
What will be the impact of the Biosecure Act on the biotechnology stock index by the end of 2024?
4
Resolution / Starting Odds
Increase • 33%
Decrease • 33%
No significant change • 34%
Stock market indices data from financial news websites
Story
U.S. House Advances Biosecure Act with 40-1 Vote to Restrict WuXi AppTec, Chinese Biotech Firms
May 15, 2024, 11:33 AM
The U.S. House of Representatives is advancing the Biosecure Act, a significant piece of legislation aimed at restructuring the U.S. pharmaceutical industry by restricting ties with Chinese biotech firms. The bill targets five key Chinese research firms, including WuXi AppTec and BGI, and mandates that dozens of biopharma companies cut ties with these suppliers by 2032. The House Oversight Committee voted 40-1 to advance the bill, which is now scheduled for a committee vote. The legislation could have substantial implications for U.S. biotechs and the future of pharmaceutical development and manufacturing in the country. Stocks affected include $XBI and $EVO.
View original story
Similar markets
Significant decline in market value • 33%
Minor impact on market value • 33%
No impact on market value • 34%
Reformulate supply chains • 33%
Seek exemptions • 33%
Challenge the Act legally • 34%
Increase • 33%
Decrease • 33%
No significant change • 34%
Gene therapy • 25%
Artificial intelligence in medicine • 25%
Vaccine development • 25%
Remain focused on current sectors • 25%
Significant stock value increase • 33%
Moderate stock value increase • 33%
No significant change • 34%
More firms investigated • 25%
Sanctions imposed • 25%
No significant actions • 25%
Other actions • 25%
Increase by 10% or more • 25%
Increase by less than 10% • 25%
No significant change • 25%
Decrease • 25%
Stock prices increase • 33%
Stock prices decrease • 33%
No significant change • 34%